GLP-1 Agonists Show Promise in Managing Psoriatic Disease
Recent discussions at Fall Clinical 2026 highlight the metabolic benefits of GLP-1 agonists for patients with psoriatic disease.
GLP-1 agonists may significantly reduce metabolic risks associated with psoriatic disease.
Psoriasis is linked to obesity, which complicates treatment outcomes.
Holistic approaches combining skin treatment and weight management show improved patient health.
At the Fall Clinical 2026 conference, Dr. Joel Gelfand emphasized the importance of GLP-1 agonists in addressing the metabolic risks linked to psoriatic disease. Gelfand, a prominent dermatologist and professor at the University of Pennsylvania, discussed how these medications can play a crucial role in managing not just the skin symptoms but also the underlying metabolic issues that many patients face.
Historically, psoriasis has been viewed primarily as a skin condition; however, recent insights suggest it is also an inflammatory metabolic disease. Gelfand pointed out that obesity is closely associated with psoriasis, exacerbating its severity and increasing the likelihood of developing psoriatic arthritis. He noted that many patients continue to experience systemic inflammation even after their skin symptoms have improved, highlighting the need for a more comprehensive treatment approach.
Data from the TOGETHER-PsO trial indicates that GLP-1 agonists can provide significant metabolic benefits for patients with psoriasis. Gelfand stated that those who do not receive these benefits are at a higher risk for serious health issues, including stroke and coronary disease. He shared that the positive feedback from colleagues who prescribe GLP-1s reflects a growing recognition of their efficacy in improving both skin and overall health outcomes for patients.
The implications of these findings extend beyond individual patient care. As healthcare providers increasingly adopt a holistic approach to treating psoriatic disease, the integration of metabolic management into dermatological care could lead to better long-term health outcomes for patients. This shift may also influence treatment protocols and guidelines within dermatology and related fields.
Looking ahead, ongoing research and clinical trials will further elucidate the role of GLP-1 agonists in psoriatic disease management. As the medical community continues to explore these connections, future conferences and studies will likely focus on refining treatment strategies that encompass both dermatological and metabolic health, aiming for sustained remission and improved quality of life for patients.
